Abstract

Background:   The incidence of morbid obesity is sharply increasing throughout the world. Obesity, and the accompanying elements of metabolic syndrome (dyslipidemia, hypertension, and diabetes mellitus), Increases the incidence and severity of cardiovascular disorders among patients. Bariatric surgery has the best efficacy regarding the management of obesity.

Objective: To assess the efficacy of sleeve gastrectomy in weight loss and improvement of co-morbidities related to obesity, especially diabetes, dyslipidaemias, hypertension, and osteoarthritis symptoms.  

Patients and methods:  A prospective data collection of 100 patients underwent laparoscopic sleeve gastrectomy between April 2015 and June 2018 have been collected throughout a year. 

Results: Mean EWL was 63.5%. Mean HBA1c has decreased from 8.5 to 6.4. Remission has occurred in 52% of hypertensive, 56% of osteoarthritis   and 67% of obstructive sleep apnea syndrome patients. 

Conclusion: LSG is a secure technique, it has a low incidence of major complications. It has a high success rate regarding the loss of weight and improvement/resolution of co-morbidities related to obesity. 

Keywords: LSG laparoscopic sleeve gastrectomy, co_morbidities